terbutaline profile

Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5403
CHEMBL ID	1760
CHEBI ID	9449
SCHEMBL ID	4391
MeSH ID	M0021177

Synonym
BRD-A50157456-065-02-4
gtpl560
KBIO1_000078
DIVK1C_000078
5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
bricyn
terbutalin
1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-
terbutaline [inn:ban]
bricaril
brican
5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol
brn 2370513
einecs 245-385-8
terbutalinum [inn-latin]
terbutalino [inn-spanish]
terbutalina [dcit]
bricar
benzyl alcohol, alpha-((t-butylamino)methyl)-3,5-dihydroxy-
brethine
SPECTRUM_001030
SPECTRUM5_001262
PRESTWICK3_000391
BSPBIO_002066
(+-)-5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol
(+-)-terbutaline
1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-, (+-)-
LOPAC0_001126
PDSP2_000157
OPREA1_823972
PRESTWICK2_000391
IDI1_000078
BSPBIO_000601
PDSP1_000158
BPBIO1_000663
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol, 5
terbutaline,(+/-)
bdbm25770
AB00053548
23031-25-6
C07129
terbutaline
DB00871
KBIO3_001566
KBIO2_001510
KBIO2_006646
KBIOSS_001510
KBIO2_004078
KBIOGR_001539
PRESTWICK1_000391
SPBIO_002522
SPBIO_001453
NINDS_000078
PRESTWICK0_000391
SPECTRUM3_000593
SPECTRUM4_000870
SPECTRUM2_001327
NCGC00089821-02
NCGC00016010-06
L000594
asthmasian (tn)
terbutaline (inn)
D08570
chebi:9449 ,
CHEMBL1760
asthmasian
5-[2-(tert-butylamino)-1-oxidanyl-ethyl]benzene-1,3-diol
A816514
CCG-205201
NCGC00016010-03
NCGC00016010-04
terbutalinum
n8onu3l3pg ,
unii-n8onu3l3pg
terbutalina
terbutalino
AKOS015889885
5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-benzenediol
terbutaline [inn]
terbutaline [who-dd]
terbutaline [mi]
5-[(1rs)-2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
bambuterol hydrochloride impurity a [epimpurity]
(rs)-5-(2-(tert-butylamino)-1-hydroxyethyl)benzene-1,3-diol
terbutaline [vandf]
1,3-benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-
SCHEMBL4391
1-(3',5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol
bricanyl (salt/mix)
benzyl alcohol, .alpha.-((t-butylamino)methyl)-3,5-dihydroxy-
5-[2-(tert-butylamino)-1-hydroxyethyl]-1,3-benzenediol #
brethaire (salt/mix)
terbutaline sulfate (salt/mix)
5-(2-(tert-butylamino)-1-hydroxyethyl)benzene-1,3-diol
AB00053548_15
DTXSID7021310 ,
SR-01000000174-2
sr-01000000174
46719-29-3
J-014950
SBI-0051094.P004
FT-0674864
Q424340
23031-25-6 (free base)
1164563-86-3
BRD-A50157456-065-12-3
SDCCGSBI-0051094.P005
NCGC00016010-16
aerodur; brican; bricar
terbutaline 1000 microg/ml in acetonitrile
EN300-151467
CS-0013822
HY-B0802A
r03cc03
r03ac03
dtxcid001310

Excerpt	Reference
"Terbutaline sulphate (TS) is a selective short-acting β"	( Andrade, S; Loureiro, JA; Oliveira, N; Pereira, MC; Ramalho, MJ, 2021)
"Terbutaline is a β-agonist that used as growth promoters to improved carcass chemical composition of chicks without residues. "	( El-Shenawy, AM; Fadl, SE; Nassef, E; Sakr, OA; Salem, NE; Zaki, RH, 2019)
"Terbutaline is a β"	( Beng, H; Jayachandra, R; Li, J; Tan, W; Wu, J; Zhang, H, 2018)
"Terbutaline is a prohibited drug except for athletes with a therapeutic use exemption certificate; terbutaline's effects on endurance performance are relatively unknown. "	( Chester, NJ; Dickinson, JW; Loosemore, M; Molphy, J; Whyte, G, 2019)
"Terbutaline is a β-2 agonist available in oral dosage form."	( Cheng, JW; Miles, A; Shulan, A, 2013)
"Terbutaline is a fast-acting beta(2)-adrenergic agonist used in the treatment of obstructive pulmonary diseases. "	( Guddat, S; Gütschow, M; Kohler, M; Orlovius, AK; Parr, MK; Schänzer, W; Thevis, M, 2009)
"Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation."	( Coons, JC; Kormos, R; Schonder, K; Shullo, M, 2004)
"Terbutaline is a beta-adrenergic receptor antagonist that acts as a bronchodilator in the treatment of asthma and chronic bronchitis. "	( Zhang, Y; Zhang, ZR, 2004)
"Terbutaline is a selective beta 2 agonist used predominantly in the treatment of asthma. "	( Bradley, D; Dean, S; Gibson, R; Kendall, MJ; Worthington, DJ, 1982)
"Terbutaline (T) is a beta-adrenergic compound which is commonly employed as a tocolytic agent in preterm labor. "	( Cotton, DB; Goldstein, DA; Lipson, LG; Strassner, HT, 1981)
"Terbutaline is a widely used, selective beta 2-adrenergic agonist whose penetration into brain has not been demonstrated in laboratory animals. "	( Basmadjian, GP; Hsu, CH; Robinson, CP, 1994)
"Terbutaline is a safe bronchodilator drug when administered orally in 2.5-mg doses for children with chronic asthma in this range of ages and weights, with minimal cardiovascular side effects and effective bronchodilation."	( Gavani, UD; Hyde, JS; Khurana, S; Manaligod, LM, 1979)
"Terbutaline is a vasodilator, a sympathomimetic beta2-receptor stimulator."	( Balldin, U; Linér, M, 1978)
"Terbutaline is a beta-sympathomimetic agent that has gained wide use in obstetrics as a tocolytic agent. "	( Loughead, JL; Thorkelsson, T, 1991)
"Terbutaline is a beta 2-agonist and administered as the racemic mixture. "	( Borgström, L; Liu, CX; Walhagen, A, 1989)
"Terbutaline seems to be a coronary vasodilator in dogs."	( Diamant, B; Hansen, PB; Hjelms, E; Steiness, E; Waldorff, S, 1988)

Excerpt	Reference
"Terbutaline has a direct effect on the fetal heart apart from the effect of uterine relaxation."	( Abdelhak, Y; Roque, H; Young, BK, 2011)
"Terbutaline have been reported to have anti-inflammatory activity. "	( Abbas Bukhari, SN; Akram, M; Alamgeer, -; Alotaibi, NH; Irfan, HM; Jabbar, Z; Khan, AQ; Munir, MU; Rasul Niazi, Z; Sarwar, M, 2022)
"Terbutaline has been used as a foetal resuscitation measure to improve the intrapartum foetal heart rate abnormalities and neonatal outcome for suspected foetal compromise. "	( Azny, MY; Gayathiri, M; Sakinah, A; Zahar, AZ, 2023)
"Terbutaline has a direct effect on the fetal heart apart from the effect of uterine relaxation."	( Abdelhak, Y; Roque, H; Young, BK, 2011)
"Terbutaline has been shown to accelerate the rate of alveolar fluid clearance and augment surfactant secretion."	( Bai, C; Chen, Z; Jiang, J; Li, S; Song, Y; Wang, X; Wu, X, 2011)
"Terbutaline has direct effects on the cardiac conduction system, but when used to treat preterm labor it is rarely associated with clinically significant cardiac arrhythmias. "	( Carson, MP; Fisher, AJ; Scorza, WE, 2002)
"Terbutaline has been determined in milk and plasma from 4 nursing mothers treated with Bricanyl tablets (2.5 or 5 mg, 3 times daily) because of obstructive lung disease. "	( Boréus, LO; de Château, P; Lindberg, C; Lindström, B; Lönnerholm, G; Nyberg, L, 1984)
"Terbutaline has been used in obstetrics to treat premature labor. "	( Ayromlooi, J; Desiderio, DM; Tobias, M, 1981)
"Terbutaline has little effect on the restrictive ventilatory deficit after CABG but does improve the efficiency of oxygenation in the early postoperative period."	( Saunders, NR; Waller, DA, 1996)
"Terbutaline has also been reported to raise HDL cholesterol."	( Glueck, CJ, 1985)
"Terbutaline sulfate has been selected as a suitable compound for evaluation of this inhaler."	( Wetterlin, K, 1988)

Excerpt	Reference
"Terbutaline failed to increase lung fluid absorption in rats given the specific alpha-ENaC siRNA-generating plasmid (pSi-4)."	( Folkesson, HG; Li, T, 2006)
"Terbutaline resulted in lower median contraction frequency per 10 minutes (2.9 [25-75 percentile, 1.7- 3.3] vs 4 [25-75 percentile, 2.5- 5]; P < .002) and reduced tachysystole (1.8% vs 18.9%; P = .003)."	( Caughey, AB; Druzin, ML; El-Sayed, YY; Pullen, KM; Riley, ET; Taylor, L; Waller, SA, 2007)
"Terbutaline can increase gene expression of VEGF in rat astrocytes after induction by NE and burn serum."	( Wang, YM; Yang, ZC, 2007)
"(+)-terbutaline did not inhibit the effects of (-)-terbutaline in these tissues."	( Jeppsson, AB; Johansson, U; Waldeck, B, 1984)
"terbutaline because of bronchoconstriction (dosage not documented)."	( Schaarschmidt, S; Standl, T, 1997)
"Terbutaline induced an increase in serum lactate concentration but did not influence the lactate response to exercise."	( Gavhed, D; Holmér, I; Jorfelt, L; Larsson, K; Larsson, L; Ohlsén, P, 1997)
"Terbutaline did not increase the amiloride-sensitive Na+ conductance."	( Ingbar, DH; Jiang, X; O'Grady, SM, 1998)
"Terbutaline evoked an increase in the forskolin response but no desensitization of receptor-mediated responses."	( Auman, JT; Seidler, FJ; Slotkin, TA; Tate, CA, 2002)
"Terbutaline did not produce a significant effect upon blood gases or blood pH."	( Fisher, JW; Gross, DM, 1978)
"Terbutaline caused an increase in heart rate, respiration rate and minute volume."	( Stepanek, J, 1978)
"The terbutaline-induced increase was the same in the upper and lower pelvis."	( Kondo, S; Morita, T; Tashima, Y, 1992)
"Terbutaline caused an increase in VA/Q inequality in patients having PaO2 values greater than 60 mm Hg which resulted in a moderate fall in the PaO2."	( Andersen, JB; Eliasen, K; Heslet, L; Qvist, J; Ringsted, CV, 1989)
"Terbutaline caused a 23% increase in PEF and a 37% increase in FEV1 at five minutes, and a 40% and 58% increase at 15 minutes."	( Clarke, SW; Millar, AB; Pavia, D; Spiteri, MA, 1988)

Excerpt	Reference
"Terbutaline treatment reduced the number of osteogenic cells."	( Bai, H; Lin, M; Liu, C; Liu, Y; Wang, Z; Xiao, C; Zhang, J, 2021)
"Terbutaline treatment of the rats with ALI resulted in significant differences in PaO2, oxygenation index, and EVLW from those in ALI group without treatment. "	( He, L; Huang, DX; Li, TP, 2009)
"Terbutaline treatment did not affect alpha-, beta-, or gamma-ENaC mRNA or alpha-ENaC protein steady-state levels, but increased total cellular levels and rate of synthesis of alpha(1)-Na(+)-K(+)-ATPase protein in FDLE in the absence of any change in alpha(1)-Na(+)-K(+)-ATPase mRNA."	( Duan, W; Gandhi, S; O'Brodovich, H; Otulakowski, G; Rahman, MS; Sarangapani, A, 2010)
"In terbutaline-treated rats with ARDS, the EVLW content were lower than that of non-treated rats, but still higher than that of the control rats."	( He, L; Li, TP; Zhu, LH, 2008)
"Terbutaline-treated women, however, were significantly more likely to have a serum glucose level in excess of 140 mg/dl than were women treated with ritodrine (13 of 26 versus 6 of 29, p less than 0.05)."	( Ashmead, G; Caritis, SN; Heddinger, LA; Toig, G, 1984)
"Both terbutaline treatments resulted in a significant increase in forced expiratory volume in one second, as compared with placebo (P less than 0.001), but treatment with the tube-spacer aerosol produced significantly more improvement than did treatment with the conventional aerosol (P less than 0.01)."	( Pedersen, S, 1983)
"Terbutaline treatment of CREAE rats lowered the splenocyte receptor number to normal values."	( Arnason, BG; Chelmicka-Schorr, E; Kim, DH; Muthyala, S; Wiegmann, K, 1995)
"Terbutaline pretreatment significantly decreased feeding elicited by PYY in a dose-dependent fashion."	( Hagan, MM; Moss, DE, 1993)
"Terbutaline treatment was associated with significantly higher rates of anomalies than in controls at all dosages used, whereas ritodrine induced significantly more anomalies at or above doses of 4.6 x 10(-9) mol per embryo. "	( Kolesari, GL; Kuhlmann, RS; Lawrence, JM; Lenselink, DR, 1994)
"Terbutaline pretreatment desensitized the vascular response to isoproterenol, resulting in a fourfold increase in the dose of isoproterenol required to produce 10% vasodilation (geometric mean after terbutaline, 100.8 ng/min; without terbutaline, 26.7 ng/min; p < 0.001)."	( Deegan, R; Stein, M; Wood, AJ, 1993)
"The terbutaline-treated group in contrast to the magnesium sulphate-treated group had reduced uterine activity as measured by Montevideo units (p < 0.002)."	( Chauhan, SP; Cleveland, RS; Dockery, JR; Magann, EF; Martin, JN; Morrison, JC, 1993)
"Terbutaline treatment elicited marked attenuation (approximately 75% reductions) of isoprenaline-induced cyclic AMP accumulation in the alveolar macrophages."	( Hjemdahl, P; Larsson, K; Zetterlund, A, 1996)
"2. Terbutaline treatment caused a significant reduction in isoprenaline (1 nM-10 microM)-induced increases in lymphocyte cyclic AMP content; the maximal increase was 14 +/- 3 pmol/10(6) cells before and 7 +/- 2 pmol/10(6) cells (n = 9, P < 0.05) after terbutaline treatment."	( Brodde, OE; Poller, U; Werner, C, 1997)
"Oral terbutaline treatment decreases beta-adrenoceptor sensitivity in alveolar macrophages in vivo."	( Hjemdahl, P; Larsson, K; Zetterlund, A, 2001)
"Terbutaline treatment decreased beta-receptor number and isoproterenol-stimulated cyclic adenosine monophosphate (cAMP) generation in natural killer cells, helper T cells, and suppressor/cytotoxic T cells but not in B cells."	( Fowler, P; Maisel, AS; Michel, MC; Motulsky, HJ; Rearden, A, 1989)
"Terbutaline pretreatment did not prevent the pulmonary hypertension that characteristically occurs after endotoxin injection, nor did it decrease the initial fall in platelet count, leukocyte count, arterial oxygen tension (PaO2), or respiratory compliance (t = 30)."	( Christenson, JT; Sigurdsson, GH, 1988)
"Terbutaline treatment suppressed plasma and urinary levels of epinephrine significantly without any effect on norepinephrine."	( Keyzer, JJ; Koëter, GH; Meurs, H; Postma, DS, 1986)
"Terbutaline-treated animals developed arrhythmias during more treatment cycles (50%) and at lower drug concentrations, whereas hexaprenaline-treated animals developed arrhythmias at higher drug concentrations, with an overall arrhythmia frequency of 14%."	( Hankins, GD; Hauth, JC, 1985)
"24h treatment with terbutaline stimulated these currents in normoxia and hypoxia, although stimulation was less in the latter."	( Baloglu, E; Bärtsch, P; Ke, A; Loeh, B; Mairbäurl, H, 2010)
"Treatment with terbutaline in the Pa-instilled group significantly increased basal AFC compared with the saline and Pa group, (respectively 22.3 ± 1.3% versus 12.5 ± 4.7%, p < 0.001)."	( Guery, B; Kipnis, E; Kipris, E; Robriquet, L, 2011)
"Treatment with terbutaline was continued for 13 days and was well tolerated."	( Coons, JC; Kormos, R; Schonder, K; Shullo, M, 2004)
"Pretreatment with terbutaline was found to attenuate both the wheal and the flare reactions to allergen throughout the observation period of 150 min but only the effect on the wheal response reached statistical significance (P less than 0.01)."	( Grönneberg, R; Hägermark, O; Strandberg, K, 1980)
"Pretreatment with terbutaline did produce small but nonsignificant increases in aerobic fractional utilization (percent peak VO2 on drug: 65.9%, 72.6%, and 76.7% vs."	( Aitchison, TC; Paton, JY; Thomson, KJ; Unnithan, VB, 1994)
"Treatment with terbutaline CR alone or the combination was preferred by as many patients as was treatment with ipratropium alone."	( Elo, J; Mansury, L; Tammivaara, R, 1993)
"Treatment with terbutaline eliminated this change in group T at 6 hrs after extubation."	( Saunders, NR; Waller, DA, 1996)
"Pretreatment with terbutaline, aminophylline or DBcAMP prevented the increases in both PAP and lung weight (P <0.001)."	( Chang, ML; Chen, HI; Hsu, K; Wang, D; Wu, CP, 1996)
"Pretreatment with terbutaline and surfactant significantly limited the increase of lung resistance to +36 and +34%, respectively."	( Fabel, H; Heinrich, U; Hohlfeld, J; Hoymann, HG; Molthan, J, 1997)
"Treatment with terbutaline, a Na/K-ATPase-stimulating drug, resulted in attack-free periods of approximately 9 months, after which the attacks reoccurred."	( Andersen, PE; Djurhuus, MS; Jensen, BM; Klitgaard, NA; Schrøder, HD, 1998)
"Pretreatment with terbutaline (100 micrograms/kg) reduced the fall induced by dry-air challenge in Taw by 37% and the subsequent rise in Rcs by 87%."	( Chen, HI; Chou, CL; Freed, AN; Hsu, K; Wang, D, 1992)
"Treatment with terbutaline in Turbuhaler was preferred by a majority of children and parents."	( Ribeiro, LB; Wirén, JE, 1990)
"Thus treatment with terbutaline for 1 day did not result in any rebound increase in bronchial responsiveness."	( Britton, JR; Higgins, BG; Knox, AJ; Tattersfield, AE; Vathenen, AS, 1988)
"Treatment with terbutaline and magnesium sulfate was unsuccessful in alleviating the uterine hypertonus, necessitating cesarean section."	( Carpenter, RJ; Moise, KJ, 1988)

Role	Description
beta-adrenergic agonist	An agent that selectively binds to and activates beta-adrenergic receptors.
EC 3.1.1.7 (acetylcholinesterase) inhibitor	An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.
anti-asthmatic drug	A drug used to treat asthma.
bronchodilator agent	An agent that causes an increase in the expansion of a bronchus or bronchial tubes.
sympathomimetic agent	A drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
tocolytic agent	Any compound used to suppress premature labour and immature birth by suppressing uterine contractions.
hypoglycemic agent	A drug which lowers the blood glucose level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
phenylethanolamines	An ethanolamine compound having a phenyl (substituted or unsubstituted) group on the carbon bearing the hydroxy substituent.
resorcinols	Any benzenediol in which the two hydroxy groups are meta to one another.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glp-1 receptor, partial	Homo sapiens (human)	Potency	0.1636	0.0184	6.8060	14.1254	AID624148
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	0.2239	0.1000	20.8793	79.4328	AID588453
GLS protein	Homo sapiens (human)	Potency	7.9433	0.3548	7.9355	39.8107	AID624146
arylsulfatase A	Homo sapiens (human)	Potency	37.9330	1.0691	13.9551	37.9330	AID720538
beta-2 adrenergic receptor	Homo sapiens (human)	Potency	10.3225	0.0058	6.0263	32.6427	AID485366
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.7569	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	134.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-2 adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	3.1623	0.0000	0.3111	10.0000	AID606103
Beta-2 adrenergic receptor	Homo sapiens (human)	Kd	68.4271	0.0000	0.6288	8.9130	AID1798580; AID426242; AID770362
Beta-1 adrenergic receptor	Homo sapiens (human)	Kd	101.3852	0.0001	0.8039	10.0000	AID1798580
Beta-3 adrenergic receptor	Homo sapiens (human)	Kd	101.3852	0.0001	0.7631	8.9130	AID1798580
Beta-adrenergic receptor kinase 1	Homo sapiens (human)	Kd	7.4000	0.1700	5.5791	22.4940	AID1799821
Beta-2 adrenergic receptor	Bos taurus (cattle)	Kd	3.9800	0.0006	1.4775	9.1200	AID40694
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-2 adrenergic receptor	Bos taurus (cattle)	Concentration	1,000,000.0000	1.0000	5.5000	10.0000	AID40688
Beta-2 adrenergic receptor	Bos taurus (cattle)	KD app	4.4800	0.0370	1.1774	4.4800	AID40687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
diet induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
regulation of sodium ion transport	Beta-2 adrenergic receptor	Homo sapiens (human)
transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor-mediated endocytosis	Beta-2 adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome to lysosome transport	Beta-2 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase A signaling	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of bone mineralization	Beta-2 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-2 adrenergic receptor	Homo sapiens (human)
bone resorption	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of mini excitatory postsynaptic potential	Beta-2 adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of autophagosome maturation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of lipophagy	Beta-2 adrenergic receptor	Homo sapiens (human)
cellular response to amyloid-beta	Beta-2 adrenergic receptor	Homo sapiens (human)
response to psychosocial stress	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of AMPA receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-1 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-1 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-1 adrenergic receptor	Homo sapiens (human)
fear response	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of circadian sleep/wake cycle, sleep	Beta-1 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-1 adrenergic receptor	Homo sapiens (human)
receptor-mediated endocytosis	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
carbohydrate metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Beta-3 adrenergic receptor	Homo sapiens (human)
energy reserve metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-3 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-3 adrenergic receptor	Homo sapiens (human)
eating behavior	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-3 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-3 adrenergic receptor	Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signal	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
tachykinin receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
heart development	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
viral genome replication	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
receptor internalization	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
positive regulation of catecholamine secretion	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of striated muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
symbiont entry into host cell	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cardiac muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of relaxation of smooth muscle	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
regulation of the force of heart contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
receptor-mediated endocytosis	Beta-2 adrenergic receptor	Bos taurus (cattle)
regulation of smooth muscle contraction	Beta-2 adrenergic receptor	Bos taurus (cattle)
positive regulation of MAPK cascade	Beta-2 adrenergic receptor	Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Bos taurus (cattle)
positive regulation of autophagosome maturation	Beta-2 adrenergic receptor	Bos taurus (cattle)
positive regulation of lipophagy	Beta-2 adrenergic receptor	Bos taurus (cattle)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
amyloid-beta binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta2-adrenergic receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase binding	Beta-2 adrenergic receptor	Homo sapiens (human)
potassium channel regulator activity	Beta-2 adrenergic receptor	Homo sapiens (human)
identical protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein-containing complex binding	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
beta1-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-1 adrenergic receptor	Homo sapiens (human)
PDZ domain binding	Beta-1 adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-1 adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Beta-1 adrenergic receptor	Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta3-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-3 adrenergic receptor binding	Beta-3 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-3 adrenergic receptor	Homo sapiens (human)
epinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
protein kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
ATP binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
beta-adrenergic receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
beta2-adrenergic receptor activity	Beta-2 adrenergic receptor	Bos taurus (cattle)
protein homodimerization activity	Beta-2 adrenergic receptor	Bos taurus (cattle)
norepinephrine binding	Beta-2 adrenergic receptor	Bos taurus (cattle)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nucleus	Beta-2 adrenergic receptor	Homo sapiens (human)
lysosome	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
Golgi apparatus	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
apical plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Beta-1 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-3 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
cytoplasm	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cytosol	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
plasma membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cilium	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
presynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
postsynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
early endosome	Beta-2 adrenergic receptor	Bos taurus (cattle)
Golgi apparatus	Beta-2 adrenergic receptor	Bos taurus (cattle)
receptor complex	Beta-2 adrenergic receptor	Bos taurus (cattle)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (177)

Assay ID	Title	Year	Journal	Article
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID28235	Unbound fraction (plasma)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID40687	Apparent binding affinity constant to beta-2 adrenergic receptor determined using [3H]DHA	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID236916	Percentage of mass balance in hexadecane membranes model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID310711	Clearance in human	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
AID76656	Compound was tested for effective dose required for 50% of maximum response in guinea pig trachea	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID28924	Effective permeability (Pe) across a hexadecane membrane (pH 6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID19419	Partition coefficient (logD7.4)	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40688	Concentration required for maximal (95-100%) beta-2 adrenergic receptor occupancy	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID24203	Distribution coefficient in octanol/water at pH 6.5	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID218848	Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID77607	Intrinsic activity in guinea pig trachea	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID236268	Fraction absorbed in human intestine after oral administration compound was measured	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID28925	Highest effective permeability across hexadecane membrane (pH 4-8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID29423	HPLC capacity factor (k')	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID24448	Partition coefficient value and its ionic species.	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID455986	Permeability across human Caco-2 cells	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1873863	Displacement of [3H]-CGP12,177 from immobilized Halo tag-fused beta2 adrenoceptor (unknown origin) expressed in Escherichia coli BL21 (DE3)
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID592684	Apparent permeability of the compound by PAMPA	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides.
AID28234	% absorbed in human GI-tract	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID481440	Dissociation constant, pKa of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID24177	log(1/ISA) value of the compound	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID40690	Beta-2 adrenergic receptor intrinsic symphaticomimetic activity relative to salbutamol	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID20050	Human absorption A (%)	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID26576	pKa value of the compound. (extrapolated values)	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID156203	Binding to POPC/GMI liposomes using biosensor system	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26304	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1564541	Permeability across apical side to basolateral side in human Caco2 cells at 30 uM after 4 hrs by HPLC analysis	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID236913	Permeability Coefficient in Caco-2 cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID24440	Calculated partition coefficient (clogP)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID770362	Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM	2013	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19	β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID77606	Intrinsic activity (n=5) in guinea pig trachea	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID606104	Intrinsic activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr relative to formoterol	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID453204	Permeability in human skin after 48 hrs by Franz cell permeability assay	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID481446	Effective permeability across human jejunum	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID22293	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID606103	Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID445445	Permeability at pH 6.5 by PAMPA method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID770363	Induction of Mitochondrial biogenesis in rabbit RPT cells after 24 hrs by FCCP-OCR assay relative to control	2013	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19	β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID445446	Oral bioavailability in human	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID156089	Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID24420	Partition coefficient (logP)	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID18849	Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID236912	Permeability Coefficient in 2/4/A1 cell model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID781325	pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID24204	Distribution coefficient in octanol/water at pH 7.4	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID40686	Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID453203	Lipophilicity, log D of the compound	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID218847	Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID28236	Unbound fraction (tissues)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID218845	Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID15711	Calculated partition coefficient (clogP)	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID236914	Permeability Coefficient in hexadecane membranes model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID74042	Compound was tested for effective dose required for 25% of maximum response in guinea pig trachea	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID29925	Volume of distribution in man (IV dose)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID40695	Intrinsic activity was measured as concentration of beta-2 adrenergic receptor agonist required for cAMP production	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481441	Aqueous diffusivity at 37C	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID24202	Distribution coefficient in octanol/water at pH 5.5	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID40694	Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID29337	Ionisation constant (pKa)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID28679	Partition coefficient (logD6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID18861	GOF value represents multisets of log P data	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID426242	Binding affinity to human adrenergic beta2 receptor	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28233	Fraction ionized (pH 7.4)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID481444	Octanol-water partition coefficient, log P of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID21264	Effective permeability measured in human.	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1798580	3H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\	2005	British journal of pharmacology, Feb, Volume: 144, Issue:3	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1799821	Inhibition Assay from Article : \\Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.\\	1989	The Journal of biological chemistry, Aug-15, Volume: 264, Issue:23	Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.
AID1346250	Human beta2-adrenoceptor (Adrenoceptors)	2005	British journal of pharmacology, Feb, Volume: 144, Issue:3	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1402 (45.95)	18.7374
1990's	778 (25.50)	18.2507
2000's	495 (16.22)	29.6817
2010's	308 (10.10)	24.3611
2020's	68 (2.23)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	844 (26.24%)	5.53%
Reviews	139 (4.32%)	6.00%
Case Studies	176 (5.47%)	4.05%
Observational	0 (0.00%)	0.25%
Other	2,057 (63.96%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (39)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Impact of Anti- Asthmatic Medications on Salivary pH and Dental Caries Pattern in a Group of Egyptian Children With Bronchial Asthma: A Cohort Study[NCT03877874]		58 participants (Anticipated)	Observational	2021-07-31	Not yet recruiting
Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State[NCT02103374]	Phase 4	45 participants (Actual)	Interventional	2012-01-31	Completed
Success of External Cephalic Version With Immediate Spinal Anesthesia Versus Spinal Anesthesia When Attempt Without Anesthesia Has Failed: A Randomized Controlled Trial[NCT03106753]	Phase 4	34 participants (Actual)	Interventional	2017-04-12	Terminated(stopped due to Interim analysis to assess concern for spinal anesthesia and increased cesarean delivery rate.)
Gender-specific Role of the beta2-adrenergic Stimulation With Short- or Long-acting Selective Agonist in Relation to Muscle Remodelling, Function, Performance, and Anti-doping[NCT03565302]		72 participants (Anticipated)	Interventional	2018-06-25	Recruiting
The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia[NCT04481282]	Phase 2	40 participants (Anticipated)	Interventional	2020-07-08	Recruiting
Hot Flashes and Neurovascular Function in Women[NCT05193968]		120 participants (Anticipated)	Interventional	2022-02-24	Recruiting
A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma[NCT04973345]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2023-07-07	Recruiting
"A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol As-needed, or Terbutaline As-needed or Regular Use of Budesonide + Terbutaline As-needed, in Patients With Mild Intermittent Asthma"[NCT00989833]	Phase 2	66 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Ago[NCT00567476]	Phase 4	116 participants (Actual)	Interventional	2007-11-30	Completed
Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain[NCT01582646]	Phase 2	20 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to difficulty of recruitment)
As Needed Budesonide/Formoterol Combination Versus Regular Budesonide/Formoterol Combination Plus as Needed Terbutaline in Mild-Moderate Persistent Asthma[NCT00849095]	Phase 3	860 participants (Actual)	Interventional	2009-04-30	Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs[NCT04278404]		5,000 participants (Anticipated)	Observational	2020-03-05	Recruiting
Acute Tocolysis With Terbutaline vs Placebo Prior to Emergency Caesarean Delivery for Suspected Intrauterine Fetal Compromise[NCT05326269]		100 participants (Actual)	Interventional	2017-04-23	Completed
[NCT02557581]		72 participants (Anticipated)	Interventional	2015-07-31	Recruiting
A Comparison of Tolerability of 10 Inhalations of Symbicort® Turbuhaler® 160/4.5 μg and 10 Inhalations of Terbutaline Turbuhaler® 0.4 mg on Top of Symbicort® Turbuhaler® 160/4.5 μg 1 Inhalation Bid, Randomized, Double-blind, Cross Over, Phase III Study in[NCT00837967]	Phase 3	25 participants (Actual)	Interventional	2009-01-31	Completed
A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes[NCT00607503]	Phase 1	9 participants (Actual)	Interventional	2008-02-29	Completed
[NCT02712658]		10 participants (Actual)	Interventional	2015-09-30	Completed
Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration.[NCT00914797]	Phase 4	30 participants (Anticipated)	Interventional	2009-07-31	Not yet recruiting
A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Stu[NCT00839800]	Phase 3	2,091 participants (Actual)	Interventional	2009-02-28	Completed
β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation[NCT01944033]	Phase 3	250 participants (Actual)	Interventional	2013-07-31	Completed
A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler® 0.4 mg and Salbutamol Pressurized Metered Dose Inhaler (pMDI) 200 μg - a Single Blind, Single Dose, Randomized, Crossover, Phase III Study in Japanese Adult Asthma Patients[NCT01096017]	Phase 3	24 participants (Actual)	Interventional	2010-03-31	Completed
A Randomised, Double-blind, Double-dummy, Multi-site, Phase III, Single Dose, 4-way Cross-over Pharmacodynamic Study Evaluating the Efficacy of Bricanyl Turbuhaler M3 Compared to Bricanyl Turbuhaler M2 by Studying the Protective Effect on Methacholine Ind[NCT02322788]	Phase 3	95 participants (Actual)	Interventional	2015-03-31	Completed
Double-blinded Randomized Trial of Terbutaline to Shorten ICU Length of Stay in the Treatment of Status Asthmaticus in Children[NCT00124995]	Phase 4	40 participants	Interventional	2003-10-31	Completed
A Comparison of the Inflammatory Control of Asthma Provided by One Inhalation of Symbicort® Turbuhaler® 160/4.5 µg/Inhalation b.i.d. Plus As-needed Versus One Inhalation of Symbicort® Turbuhaler® 320/9 µg/Inhalation b.i.d. + One Inhalation of Pulmicort® T[NCT00244608]	Phase 3	100 participants	Interventional	2005-05-31	Completed
The Effects of ß2 Polymorphisms on Beta Selectivity After ß-adrenergic Blockade in Patients With Heart Failure[NCT00214318]		25 participants	Interventional	2005-01-31	Completed
Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation[NCT00185887]		110 participants (Actual)	Interventional	2003-10-31	Completed
A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Mul[NCT00252863]	Phase 3	1,600 participants	Interventional	2004-12-31	Completed
Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months[NCT00259766]	Phase 3	1,970 participants	Interventional	2004-04-30	Completed
Comparison of the Efficacy and Safety of Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Asthma Presenting at the Emergency Room for Moderate Exacerbation[NCT04705727]	Phase 3	102 participants (Actual)	Interventional	2021-08-23	Terminated(stopped due to Not enough recruitment in th trial)
A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD[NCT00421122]	Phase 3	315 participants (Actual)	Interventional	2006-09-30	Completed
Intravenous Terbutaline to Facilitate Epidural Catheter Placement for Parturients With Labor Pain[NCT01651962]	Phase 4	250 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Intravenous Terbutaline Versus Intravenous Nitroglycerine for External Cephalic Version: A Double-Blinded Randomized Controlled Trial in Nulliparous Women[NCT02115256]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to difficult recruitment)
The Effect of Using Terbutaline or a Reduction in Basal Insulin Infusion as a Therapeutic Agent to Prevent Delayed Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes[NCT00974051]		16 participants (Actual)	Interventional	2008-03-31	Completed
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy[NCT05494307]	Phase 2	228 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele[NCT04468568]		25 participants (Actual)	Observational	2017-10-01	Completed
Beta-Receptor SELECTivity of Carvedilol and Metoprolol Succinnate in Patients With Heart Failure: A Randomized Dose Ranging Trial (SELECT Trial)[NCT00802230]	Phase 4	25 participants (Actual)	Interventional	2002-09-30	Completed
A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma[NCT02224157]	Phase 3	4,215 participants (Actual)	Interventional	2014-11-28	Completed
An Open-label, Single-dose, 2-period Cross Over Study in Healthy Volunteers to Assess Relative Bioavailability of Terbutaline Sulphate 1.5 mg After Inhalation Via the M3 Turbuhaler Compared With the M2 Turbuhaler[NCT02178059]	Phase 1	34 participants (Actual)	Interventional	2014-08-31	Completed
A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.[NCT02149199]	Phase 3	3,850 participants (Actual)	Interventional	2014-07-07	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cord pH

Arterial cord pH level (NCT03106753)
Timeframe: Day 1

Intervention	pH (Mean)
Spinal Anesthesia Immediately for ECV.	7.2
Spinal Anesthesia if no Intervention Fails for ECV.	7.2

Newborn Birth Weight

Newborn birth weight in grams. (NCT03106753)
Timeframe: Day 1 of delivery

Intervention	grams (Mean)
Spinal Anesthesia Immediately for ECV.	3321.6
Spinal Anesthesia if no Intervention Fails for ECV.	3257.7

Number of Adverse Events During Procedure

Number of total specific adverse events such as: fetal bradycardia, emergent cesarean section, or abruption. (NCT03106753)
Timeframe: Day 1

Intervention	events (Number)
Spinal Anesthesia Immediately for ECV.	11
Spinal Anesthesia if no Intervention Fails for ECV.	5

Number of NICU Admission

Number of patients whose neonate was admitted to the NICU in each group. (NCT03106753)
Timeframe: Day 1

Intervention	Participants (Count of Participants)
Spinal Anesthesia Immediately for ECV.	1
Spinal Anesthesia if no Intervention Fails for ECV.	1

Time From Procedure to Delivery.

Number of days from procedure to delivery. (NCT03106753)
Timeframe: up to day 42

Intervention	hours (Mean)
Spinal Anesthesia Immediately for ECV.	12.6
Spinal Anesthesia if no Intervention Fails for ECV.	11.3

Number of Participants With Newborns With Apgar Score 7 or 9

Newborns with Apgar Score 7 or 9 at 5 minutes after delivery. The Apgar score is based on a total score of 1 to 10. The higher the score, the better the baby is doing after birth. A score of 7, 8, or 9 is normal and is a sign that the newborn is in good health. (NCT03106753)
Timeframe: 7 minutes and 9 minutes after delivery

Intervention	Participants (Count of Participants)
	7	9
Spinal Anesthesia if no Intervention Fails for ECV.	1	15
Spinal Anesthesia Immediately for ECV.	1	16

Number of Participants With Success Rate of External Cephalic Version to Cephalic Presentation.

Success rate will be measured by comparing the percentage of successful external cephalic versions in each group. (NCT03106753)
Timeframe: Day 1

Intervention	Participants (Count of Participants)
	Nulliparous	Multiparous
Spinal Anesthesia if no Intervention Fails for ECV.	5	3
Spinal Anesthesia Immediately for ECV.	4	3

Number of Participants With Various Mode of Delivery

Mode of delivery as incidence of spontaneous vaginal delivery, operative vaginal delivery, or cesarean section. (NCT03106753)
Timeframe: up to day 42

Intervention	Participants (Count of Participants)
	Spontaneous Vaginal Delivery	Operative Vaginal Delivery	Cesarean Section
Spinal Anesthesia if no Intervention Fails for ECV.	6	1	9
Spinal Anesthesia Immediately for ECV.	6	0	11

Numeric Rating Scale (NRS-11)

Patient discomfort rated with NRS-11. Total scale from 0-10, with higher score indicating more pain. (NCT03106753)
Timeframe: Day 1

Intervention	score on a scale (Mean)
	First procedure
Spinal Anesthesia Immediately for ECV.	2.0

Numeric Rating Scale (NRS-11)

Patient discomfort rated with NRS-11. Total scale from 0-10, with higher score indicating more pain. (NCT03106753)
Timeframe: Day 1

Intervention	score on a scale (Mean)
	First procedure	Second procedure
Spinal Anesthesia if no Intervention Fails for ECV.	6.1	2.2

Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)

Change in overall ACQ5. ACQ5 measures asthma control and a lower values shows a better asthma control, a higher value is worse. A decrease in the ACQ5 shows an improvement during the treatment period. Range of ACQ5 is 0-5, with 0 as the best value and 5 as the worst value. Further information at www.qoltech.co.uk. (NCT00989833)
Timeframe: Baseline e and 6 weeks

Intervention	units on a scale (Mean)
Budesonide/Terbutaline	-0.3
Terbutaline	-0.2
Budesonide/Formoterol	-0.4

Bronchial Responsiveness to Mannitol

Change in cumulative Mannitol dose in mg in patients with a positive mannitol provocation test at baseline (PD15) (NCT00989833)
Timeframe: Baseline and 6 weeks

Intervention	mg (Mean)
Budesonide/Terbutaline	67.26
Terbutaline	-6.15
Budesonide/Formoterol	151.87

Concentration of Exhaled Nitric Oxide

(NCT00989833)
Timeframe: 6 weeks

Intervention	ppb (Mean)
Budesonide/Terbutaline	25.9
Terbutaline	35.5
Budesonide/Formoterol	24.4

Diary Recording of Asthma Symptoms

Asthma symptoms during days with exercise (NCT00989833)
Timeframe: 6 weeks

Intervention	Percent of exercise days (Mean)
Budesonide/Terbutaline	51.1
Terbutaline	50.9
Budesonide/Formoterol	49.8

Number of Participants With an Adverse Event During the Study

(NCT00989833)
Timeframe: 6 weeks

Intervention	Participants (Number)
Budesonide/Terbutaline	13
Terbutaline	13
Budesonide/Formoterol	13

Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks

FEV1 (NCT00989833)
Timeframe: Baseline and 3 weeks

Intervention	Percent change (Mean)
Budesonide/Terbutaline	-4.07
Terbutaline	-1.19
Budesonide/Formoterol	-3.81

Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks

FEV1 (NCT00989833)
Timeframe: Baseline and Visit 6

Intervention	Percent change (Mean)
Budesonide/Terbutaline	-5.85
Terbutaline	0.61
Budesonide/Formoterol	-5.24

Use of as Needed Medication

Mean number of as needed inhalations taken before exercise (NCT00989833)
Timeframe: 6 weeks

Intervention	number of inhalations per day (Mean)
Budesonide/Terbutaline	0.6
Terbutaline	0.8
Budesonide/Formoterol	0.7

Free Days With no Rescue Medication

When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. Days with no rescue medication intake were the variable of interest for this analysis. (NCT00567476)
Timeframe: From Baseline through 20 weeks (140 days)

Intervention	Days (Mean)
Omalizumab + Conventional Therapy	73.5
Conventional Therapy	74.9

Mean Number of Puffs of Rescue Medication Taken Per Day

When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. The number of puffs taken during each 24 hour period was recorded in the patient dairy. The total number of puffs over 20 weeks of treatment was divided by the number of treatment days (140 days) to calculate the mean number of puffs per day. (NCT00567476)
Timeframe: From Baseline through 20 Weeks

Intervention	Puffs (Mean)
Omalizumab + Conventional Therapy	5.5
Conventional Therapy	6.4

Percentage of Participants Using Rescue Medication

When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. (NCT00567476)
Timeframe: From Baseline through 20 Weeks

Intervention	Percentage of participants (Number)
Omalizumab + Conventional Therapy	43.6
Conventional Therapy	44.7

Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20

The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. AQLQ of each domain is the mean of the responses to each of the questions within that domain. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment. (NCT00567476)
Timeframe: Baseline and Week 20

Intervention	Percentage of participants (Number)
Omalizumab + Conventional Therapy	70.1
Conventional Therapy	22.2

Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks

The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment. (NCT00567476)
Timeframe: Baseline and Week 20

Intervention	Percentage of participants (Number)
Omalizumab + Conventional Therapy	40.3
Conventional Therapy	2.8

Number of Asthma Exacerbation Episodes Per Participant

For the purpose of evaluating efficacy, a clinically significant asthma exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling the baseline ICS dose for at least 3 days and/or treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the above corticosteroid regimens marked the start of an asthma exacerbation episode and cessation of the additional corticosteroid regimens marked the end of an exacerbation episode. (NCT00567476)
Timeframe: From Baseline through 20 weeks

Intervention	Participants (Number)
	Patients with 1 episode	Patients with 2 episodes	Patients with 3 episodes	Patients with 4 episodes	Total number of patients with episodes
Conventional Therapy	12	6	1	1	20
Omalizumab + Conventional Therapy	25	5	3	1	34

Patient's Global Assessment of Treatment Effectiveness

"At the end of Week 20, a global evaluation of the treatment effectiveness was performed by the patient using the following scale:~Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma" (NCT00567476)
Timeframe: 20 Weeks

Intervention	Participants (Number)
	Excellent	Good	Moderate	Poor	Worsening
Conventional Therapy	3	13	10	9	2
Omalizumab + Conventional Therapy	33	30	10	3	0

Physician's Global Assessment of Treatment Effectiveness

At the end of Week 20 a global evaluation of the treatment effectiveness was performed by the investigator using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma (NCT00567476)
Timeframe: 20 Weeks

Intervention	Participants (Number)
	Excellent	Good	Moderate	Poor	Worsening
Conventional Therapy	2	4	11	18	2
Omalizumab + Conventional Therapy	22	35	13	6	0

The Mean Change From Baseline to the End of Study in AQLQ Domain Score

"AQLQ was administered to all patients at Baseline, Week 12 and Week 20, and prior to any clinic visit evaluation and drug administration.~The 32 questions in the AQLQ were divided into four domains: activity limitations, symptoms, emotional function, and environmental stimuli. AQLQ domain scores were calculated by adding the responses to each of the questions in the domain and dividing by the number of questions in the domain. Each domain score was between 1 and 7. Score 7.0 meant that the patient had no impairments due to asthma and score 1.0 indicated severe impairment." (NCT00567476)
Timeframe: Baseline and Week 20

Intervention	Units on a scale (Mean)
	Activity limitation score	Symptoms score	Emotional function score	Environmental stimuli score
Conventional Therapy	-0.2	-0.2	0.0	0.0
Omalizumab + Conventional Therapy	1.3	1.2	1.3	1.2

The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ)

The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and a score of 1.0 indicates severe impairment. (NCT00567476)
Timeframe: Baseline and Week 20

Intervention	Units on a scale (Mean)
	Baseline (n=77, 37)	At Week 20 (n=78, 36)	Change from baseline to week 20 (n=77, 36)
Conventional Therapy	3.1	3.0	-0.1
Omalizumab + Conventional Therapy	3.1	4.4	1.2

Adverse Events

Total number of adverse events (NCT00837967)
Timeframe: 3 days

Intervention	adverse events (Number)
Symbicort	14
Terbutaline	24

Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 140 min after start dosing for each treatment day

Intervention	mg/dLiters (Mean)
Symbicort	121.1
Terbutaline	129.5

Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)

The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 740 min after start dosing for each treatment day

Intervention	ms (Mean)
Symbicort	411.71
Terbutaline	414.33

Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 740 min after start dosing for each treatment day

Intervention	mEq/L (Mean)
Symbicort	4.01
Terbutaline	3.88

Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)

Intervention	mmHg (Mean)
Symbicort	115.3
Terbutaline	114.9

Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)

Intervention	beats/min (Mean)
Symbicort	70.0
Terbutaline	74.1

Asthma Control Questionnaire (ACQ)

The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here. (NCT00839800)
Timeframe: 4, 12, 24, 36 and 52 weeks after randomization

Intervention	units on a scale (Mean)
Symbicort SMART	1.162
Symbicort+Terbutaline As Needed	1.289

Asthma Symptom Score

The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst). (NCT00839800)
Timeframe: 52-week treatment period

Intervention	units on a scale (Mean)
Symbicort SMART	1.12
Symbicort+Terbutaline As Needed	1.22

Evening PEF

The mean value from a 52-week treatment period. (NCT00839800)
Timeframe: 2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period

Intervention	L/min (Mean)
Symbicort SMART	334.2
Symbicort+Terbutaline As Needed	327.8

Forced Expiratory Volume in One Second (FEV1)

The mean value for Weeks 4, 12, 24, 36 and 52 was analysed. (NCT00839800)
Timeframe: 4, 12, 24, 36 and 52 weeks after randomization

Intervention	Liter (L) (Geometric Mean)
Symbicort SMART	2.258
Symbicort+Terbutaline As Needed	2.222

Morning Peak Expiratory Flow (PEF)

The mean value from a 52-week treatment period. (NCT00839800)
Timeframe: 52-week treatment period

Intervention	Liter/minute (L/min) (Mean)
Symbicort SMART	331.8
Symbicort+Terbutaline As Needed	324.7

Nights With Awakening(s) Due to Asthma Symptoms

The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period

Intervention	Nights With Awakening(s) (Mean)
Symbicort SMART	15.7
Symbicort+Terbutaline As Needed	17.5

Number of Asthma Exacerbations

Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here. (NCT00839800)
Timeframe: up to 52 weeks

Intervention	Asthma exacerbations (Number)
Symbicort SMART	259
Symbicort+Terbutaline As Needed	363

Percentage of As-needed-free Days

An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period

Intervention	percentage of as-needed-free days (Mean)
Symbicort SMART	51.4
Symbicort+Terbutaline As Needed	47.2

Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)

An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period

Intervention	percentage of asthma-control days (Mean)
Symbicort SMART	41.7
Symbicort+Terbutaline As Needed	37.9

Symptom-free Days (no Symptoms and no Awakenings)

A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here. (NCT00839800)
Timeframe: 52-week treatment period

Intervention	symptom-free days (Mean)
Symbicort SMART	45.5
Symbicort+Terbutaline As Needed	41.6

The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study

Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment. (NCT00839800)
Timeframe: week 52

Intervention	percentage of participants (Number)
Symbicort SMART	16
Symbicort+Terbutaline As Needed	22

The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations

Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here. (NCT00839800)
Timeframe: up to 52 weeks

Intervention	percentage of participants (Number)
Symbicort SMART	71
Symbicort+Terbutaline As Needed	80

Use of As-needed Medication

The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time). (NCT00839800)
Timeframe: 52-week treatment period

Intervention	inhalations/day (Mean)
Symbicort SMART	1.21
Symbicort+Terbutaline As Needed	1.46

FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation

FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation (NCT01096017)
Timeframe: At two visits during a maximum of 15 days. FEV1 timepoints: all time points t=5, 15, 30, 60, 120, 180 and 240 minutes.

Intervention	milliLiters x minutes (Geometric Mean)
Salbutamol pMDI	617.56
Terbutaline Turbuhaler®	634.64